

A<sup>1</sup><sub>at</sub>  
the benefit of Provisional Application Serial No. 60/036,620,  
filed January 31, 1997.

IN THE CLAIMS:

Please cancel claims 1-2, 5-15, 17-25 and 27-28 without  
prejudice.

Please amend the claims as follows:

A<sup>2</sup>  
16. (Amended) A method of inducing an immunological  
response in an animal in need of such response which comprises  
administering to said animal an immunologically effective amount  
of [the] a semi-allogeneic immunogenic cell [of at least one of  
Claims 1, 2, 3, 4, 9 and 10], wherein said cell comprises an  
antigen-presenting cell expressing at least one class I MHC or  
class II MHC determinant that is syngeneic to said animal and at  
least one class I or class II MHC determinant that is allogeneic  
to said animal, and wherein said antigen-presenting cell is  
transformed with and expresses DNA coding for at least one  
antigen recognized by T cells of said animal.

A<sup>3</sup>  
B<sup>1</sup>  
26. (Amended) A method of preventing or treating a  
tumor in an animal [in need thereof] which comprises  
administering to said animal a tumor inhibiting effective amount  
of [the] a semi-allogeneic immunogenic [population of cells of at  
least one of Claim 2, 3 and 4] cell, wherein said cell comprises  
an antigen-presenting cell expressing at least one class I MHC or  
class II MHC determinant that is syngeneic to said animal and at  
least one class I or class II MHC determinant that is allogeneic  
to said animal, and wherein said antigen-presenting cell is

Ad. B1-1r  
A3  
w

transformed with and expresses DNA isolated from the tumor cells of said animal.

Please add the following claims:

29. (Added) The method of claim 16, wherein said animal has a tumor and said DNA codes for at least one tumor-associated antigen.

30. (Added) A method of inducing an immunological response in an animal having a tumor which comprises administering to said animal an immunologically effective amount of a semi-allogeneic immunogenic cell, wherein said cell comprises an antigen-presenting cell expressing at least one class I MHC or class II MHC determinant that is syngeneic to said animal and at least one class I or class II MHC determinant that is allogeneic to said animal, and wherein said antigen-presenting cell is transformed with and expresses DNA isolated from the tumor cells of said animal.

31. (Added) A method of inducing an immunological response in an animal having a tumor which comprises administering to said animal an immunologically effective amount of a semi-allogeneic immunogenic cell, wherein said cell comprises a semi-allogeneic hybrid cell formed by fusing an antigen presenting cell with a neoplastic cell, wherein said hybrid cell expresses at least one class I or class II MHC determinant that is syngeneic to said animal and at least one class I or class II MHC determinant that is allogeneic to said animal.

32. (Added) The method of claim 31, wherein said neoplastic cell is from the tumor of said animal.

33. (Added) The method according to any of claims 16 or 30-32, wherein said antigen presenting cell is further transformed with a nucleic acid molecule coding for at least one cytokine.

34. (Added) The method of claim 33, wherein said cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interferon- $\alpha$ , interferon- $\gamma$ , tumor necrosis factor, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.

35. (Added) The method according to any of claims 16 or 30-32, wherein said antigen-presenting cell is selected from the group consisting of a fibroblast, a macrophage, a B cell, and a dendritic cell.

36. (Added) The method according to any of claims 29-32, wherein said tumor is a solid tumor or a hematological tumor.

37. (Added) The method of Claim 36, wherein said tumor is selected from the group consisting of melanoma, lymphoma, plasmacytoma, sarcoma, glioma, thymoma, leukemias, breast cancer, prostate cancer, colon cancer, esophageal cancer, brain cancer, lung cancer, ovary cancer, cervical cancer and hepatoma.

38. (Added) The method according to any of claims 16 or 30-32, wherein said animal is a human subject.

39. (Added) A method of preventing or treating a tumor in an animal which comprises administering to said animal an immunologically effective amount of a semi-allogeneic immunogenic cell, wherein said cell comprises a semi-allogeneic hybrid cell formed by fusing an antigen presenting cell with a neoplastic cell, wherein said hybrid cell expresses at least one class I or class II MHC determinant that is syngeneic to said animal and at least one class I or class II MHC determinant that is allogeneic to said animal.

40. (Added) The method of claim 39, wherein said neoplastic cell is from the tumor of said animal.

41. (Added) The method according to any of claims 26 or 39-40, wherein said antigen presenting cell is further transformed with a nucleic acid molecule coding for at least one cytokine.

42. (Added) The method of claim 41, wherein said cytokine is selected from the group consisting of interleukin-1, interleukin-2, interleukin-3, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-9, interleukin-10, interleukin-11, interleukin-12, interferon- $\alpha$ , interferon- $\gamma$ , tumor necrosis factor, granulocyte macrophage colony stimulating factor, and granulocyte colony stimulating factor.

43. (Added) The method according to any of claims 26 or 39-40, wherein said antigen-presenting cell is selected from